Lessons and future directions for GBA1-targeting therapies
Lancet Neurol
.
2023 Aug;22(8):644-645.
doi: 10.1016/S1474-4422(23)00217-X.
Author
Ziv Gan-Or
1
Affiliation
1
Department of Neurology and Neurosurgery, The Neuro (Montreal Neurological Institute-Hospital), and Department of Human Genetics, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: ziv.gan-or@mcgill.ca.
PMID:
37479362
DOI:
10.1016/S1474-4422(23)00217-X
No abstract available
Publication types
Comment
MeSH terms
Glucosylceramidase* / genetics
Glucosylceramidase* / therapeutic use
Humans
Mutation
Parkinson Disease*
alpha-Synuclein
Substances
Glucosylceramidase
alpha-Synuclein